Medtronic Unveils Paradigm Veo in Fight against Diabetes

Trading Markets

At this year's annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Ljubljana, Slovenia, Medtronic announced the launch of a technology designed to provide additional protection against the risks associated with hypoglycemia.

This new device, now available in more than 50 countries outside of the United States, can automatically suspend insulin delivery when the device senses that glucose levels have fallen to or below a user-selected threshold. The company said this feature is intended to reduce the severity of low blood sugar (hypoglycemia) in situations where patients ignore or are unable to treat hypoglycemia. A dangerous and often frequent occurrence in diabetes management, hypoglycemia can be one of the most frightening aspects of living with type 1 diabetes. If left untreated, hypoglycemia can cause loss of consciousness, seizure, coma, or even death.

More.